Cleveland Diagnostics' IsoPSA gets NCCN prostate cancer listing

By LabPulse.com staff writers

May 11, 2022 -- Cleveland Diagnostics' IsoPSA prostate cancer test is now included in the National Comprehensive Cancer Network's (NCCN) guidelines for early prostate cancer detection.

The guidelines now suggest use of IsoPSA to categorize probability of high-grade prostate cancer (i.e., Gleason score equal to or greater than 3+4, and group grade of 2 or higher) before a first biopsy or after a negative biopsy, the company said.

IsoPSA is a blood-based prostate cancer test that has shown better diagnostic accuracy than prostate-specific antigen (PSA) testing, according to Cleveland Diagnostics.

Cleveland Diagnostics touts IsoPSA study
Cleveland Diagnostics is highlighting a recent study that showed its IsoPSA blood test for prostate cancer led to a 55% reduction in prostate biopsy recommendations.
Cleveland Diagnostics' prostate cancer blood test gets breakthrough status
Cleveland Diagnostics' IsoPSA blood test for prostate cancer has been designated by the U.S. Food and Drug Administration as a breakthrough device, which...

Copyright © 2022 LabPulse.com

Last Updated mp 5/11/2022 11:05:12 AM